“全网最低价”等被列入新型垄断风险，互联网卖药受影响几何

Core Viewpoint - The recent regulatory measures aim to strengthen oversight of the pharmaceutical market, particularly focusing on price transparency and fair competition among online platforms and medical institutions [1][7]. Group 1: Regulatory Framework - The State Administration for Market Regulation has issued the "Internet Platform Antitrust Compliance Guidelines," which outlines new risks such as algorithm collusion and selling below cost [2][3]. - The guidelines emphasize four fundamental principles: fairness in rules, ethical algorithms, compliance in competition, and targeted risk assessment based on industry characteristics [3]. - The "Medical Institution Price Disclosure Regulations" has been revised for the first time in 24 years, now including online hospitals and requiring detailed price disclosures for online prescriptions [1][7]. Group 2: Market Dynamics - The pharmaceutical e-commerce sector is projected to reach a sales total of 248.8 billion yuan in 2024, with third-party transaction service platforms accounting for 44% of this figure [3]. - Online platforms are seen as both rule-makers and market participants, leading to potential price wars that could impact traditional pharmacies and disrupt existing pricing management systems [4][5]. - A notable case highlighted the disparity in drug prices, where online prices were significantly lower than those in physical stores, raising concerns about market fairness [4]. Group 3: Compliance and Risks - The guidelines prohibit practices such as using promotional activities to establish vertical monopoly agreements and selling below cost without justification [5][6]. - The assessment of compliance risks will focus on the appropriateness of subsidy levels, the voluntary nature of merchant participation, and the duration of promotional activities [5][6]. - Concerns have been raised regarding the safety risks associated with promotional behaviors in the pharmaceutical sector, particularly in relation to prescription drugs [6]. Group 4: Transparency and Competition - The National Healthcare Security Administration has initiated actions to compare online drug prices with various channels to ensure fairness and prevent excessive pricing [7]. - Both regulatory approaches aim to clarify the true bottom line of drug and medical service prices, promoting healthy competition in the pharmaceutical market [8]. - Platforms must avoid practices that could lead to monopolistic behavior, such as exclusive arrangements that limit the survival of other operators [8][9].